Financial assistance available for high-cost cancer
therapies.
by Tucker, Miriam E.
WASHINGTON -- Financial assistance is available to patients
struggling with costs of the new--and extremely expensive--targeted
therapies for renal cell carcinoma as well as other advanced cancers,
Mr. James Goetz said at the annual Community Oncology Conference.
As far as the patient is concerned, the approved agents sunitinib
(Sutent), sorafenib (Nexavar), and temsirolimus (Torisel) are all in the
same cost ballpark, with each resulting in a bill of about $135,000 for
a 6-month regimen at St. Luke's Hospital and Health Network in
Bethlehem, Pa., where Mr. Goetz is the network administrator of the
Oncology Service Line.
"We're seeing more and more patients on Medicare without
secondary insurance, those who are underinsured, and who have no
insurance .... The onus of these expensive drugs is on the
patient," he said.
But there are places to turn for help, according to Mr. Goetz.
First, all the manufacturers offer patient assistance programs,
accessible on their Web sites (www.sutent.com, www.nexavar.com,
www.torisel.com). Patients fill out a form and submit it to see if they
qualify for financial assistance. "Sometimes it's successful,
sometimes it isn't," he said.
Nonprofit organizations can help fill in the gaps. A highly
recommended resource is the Patient Advocate Foundation (PAF;
www.patientadvocate.org or 800-5325274), whose mission is "to
safeguard patients through effective mediation assuring access to care,
maintenance of employ ment, and preservation of their financial
stability relative to their diagnosis of life-threatening or
debilitating diseases."
The foundation employs professional case managers and attorneys to
assist patients with a wide range of access-to-care issues, including
pre-authorization, insurance appeals, and assistance with expedited
applications for Social Security disability, Medicare, Medicaid, SCHIPs,
and other programs. It also provides assistance with job retention, debt
crisis, housing, transportation to medical treatment, and child care. In
addition, it offers a "Co-Pay Relief" program for those who
are already insured, and an assistance program geared specifically to
patients with colorectal cancer. "The PAF is a great resource that
we give to many of our patients," Mr. Goetz said.
Other potentially helpful nonprofit patient assistance
organizations listed by Mr. Goetz include the following:
* Patient Access Network Foundation (www.patientaccessnetwork.org
or 866316-7263) assists with medical expenses including medications,
co-payments, insurance, and certain other out-of-pocket health-related
expenses.
* Healthwell Foundation (www.healthwellfoundation.org or
800-875-8416) also assists with medical expenses, including medications,
co-pays, insurance, and some other out-of-pocket expenses.
* Cancer Care (www.cancercare.org or 800-813-4673) assists with
transportation, chemotherapy, pain medications, home care, and some
child care issues.
Mr. Goetz declared no financial interest in any of the relevant
manufacturers. SKIN ALLERGY NEWS and Community Oncology are both
published by Elsevier.
BY MIRIAM E. TUCKER
Senior Writer
COPYRIGHT 2008 International Medical News
Group Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2008 Gale, Cengage Learning. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.